Purchase this article with an account.
Emiliano S. Lopez, Juan Croxatto, Juan E. Gallo, Nanomedicine & Vision Group, Universidad Austral,Buenos Aires, Argentina; Poloxamer Improves the Duration of Action of Suramab to Inhibit Corneal Angiogenesis. Invest. Ophthalmol. Vis. Sci. 2011;52(14):6383.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
In previous studies we showed the antiangiogenic effect of Suramab (3mg/kg of bevacizumab and 10mg/kg of suramin) in an animal model of corneal neovascularization. In the present study we aimed at evaluating the effect of Poloxamer (a polymer) to prolong the effect of suramab.
Corneal NV was induced in three groups of Sprague Dawley rats, applying a filter paper disc soaked in 1M Na (OH) on the central cornea. Group one (n=6) was treated after injury with subconjunctival Suramab + Poloxamer (SP). Group two (n=6) was treated with subconjunctival Suramab (S). Group three (n=5) received no treatment. At 15 days of follow up animals were sacrificed and perfused with black drawing ink. Digital photographs were taken and the area of neovascularisation (ANV) was calculated using the jimage programme.
In the two treated groups the ANV was remarkably inferior compared to that found in controls (p<0,05). Besides, the ANV was lower in SP animals compared to that seen in S animals. No adverse effects were observed at 15 days of follow-up.
Duration of the effect with SP was longer than that obtained with S. The presence of Poloxamer, known to modulate control release of biological agents, seems to have a favorable effect on suramab subconjunctivally administered. Further experiments are necessary to confirm the usefulness of this combination in ocular therapy.
This PDF is available to Subscribers Only